Selected research
Industry Research
Pharmacogenomics Technology (Theranostics & CDx) Industry Research Report 2026
Market perspective
Global Pharmacogenomics Technology (Theranostics & CDx) key players include Illumina, F. Hoffmann-La Roche, Agilent, Abbott, Thermo Fisher Scientific etc. Global top three players hold a share over 65%. North America is the largest market, with a share about 40%, followed by Europe and China, both have a share about 40 percent.
Report Scope
This report quantifies the global Pharmacogenomics Technology (Theranostics & CDx) market in terms of revenue (US$ million) and, where applicable, service volume (Kiloton), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
Read the full market overview
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/Kiloton) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Pharmacogenomics Technology (Theranostics & CDx).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pharmacogenomics Technology (Theranostics & CDx) Market by Company
Illumina
F. Hoffmann-La Roche
Agilent
Abbott
Thermo Fisher Scientific
Qiagen
Guardant Health
MGI Tech
Amoy Diagnostics
BGI Group
Pharmacogenomics Technology (Theranostics & CDx) Segment by Type
Instruments
Reagents and Consumables
Other
Pharmacogenomics Technology (Theranostics & CDx) Segment by Application
Tumour
Diabetes
Mental Illness
Cardiovascular Disease
Other
Pharmacogenomics Technology (Theranostics & CDx) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmacogenomics Technology (Theranostics & CDx) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pharmacogenomics Technology (Theranostics & CDx) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmacogenomics Technology (Theranostics & CDx).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Pharmacogenomics Technology (Theranostics & CDx) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Instruments
- Reagents and Consumables
- Other
Applications
- Tumour
- Diabetes
- Mental Illness
- Cardiovascular Disease
- Other
Companies covered
- Illumina
- F. Hoffmann-La Roche
- Agilent
- Abbott
- Thermo Fisher Scientific
- Qiagen
- Guardant Health
- MGI Tech
- Amoy Diagnostics
- BGI Group
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Pharmacogenomics Technology (Theranostics & CDx) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Instruments
- 2.2.3 Reagents and Consumables
- 2.2.4 Other
- 2.3 Pharmacogenomics Technology (Theranostics & CDx) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Tumour
- 2.3.3 Diabetes
- 2.3.4 Mental Illness
- 2.3.5 Cardiovascular Disease
- 2.3.6 Other
- 2.4 Assumptions and Limitations
3 Pharmacogenomics Technology (Theranostics & CDx) Breakdown Data by Type
- 3.1 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Type (2021-2026)
- 3.2 Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Type (2027-2032)
4 Pharmacogenomics Technology (Theranostics & CDx) Breakdown Data by Application
- 4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Application (2021-2026)
- 4.2 Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Perspective (2021-2032)
- 5.2 Global Pharmacogenomics Technology (Theranostics & CDx) Growth Trends by Region
- 5.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Region (2021-2026)
- 5.2.3 Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Region (2027-2032)
- 5.3 Pharmacogenomics Technology (Theranostics & CDx) Market Dynamics
- 5.3.1 Pharmacogenomics Technology (Theranostics & CDx) Industry Trends
- 5.3.2 Pharmacogenomics Technology (Theranostics & CDx) Market Drivers
- 5.3.3 Pharmacogenomics Technology (Theranostics & CDx) Market Challenges
- 5.3.4 Pharmacogenomics Technology (Theranostics & CDx) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Revenue
- 6.1.1 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Revenue (2021-2026)
- 6.1.2 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Players (2021-2026)
- 6.2 Global Pharmacogenomics Technology (Theranostics & CDx) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Pharmacogenomics Technology (Theranostics & CDx) Head Office and Area Served
- 6.4 Global Pharmacogenomics Technology (Theranostics & CDx) Players, Product Type & Application
- 6.5 Global Pharmacogenomics Technology (Theranostics & CDx) Manufacturers Established Date
- 6.6 Global Pharmacogenomics Technology (Theranostics & CDx) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032)
- 7.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026)
- 7.4 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032)
- 8.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026)
- 8.4 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032)
- 9.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032)
- 10.2 South America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026)
- 10.4 South America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size (2021-2032)
- 11.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Illumina
- 12.1.1 Illumina Company Information
- 12.1.2 Illumina Business Overview
- 12.1.3 Illumina Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2021-2026)
- 12.1.4 Illumina Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
- 12.1.5 Illumina Recent Developments
- 12.2 F. Hoffmann-La Roche
- 12.2.1 F. Hoffmann-La Roche Company Information
- 12.2.2 F. Hoffmann-La Roche Business Overview
- 12.2.3 F. Hoffmann-La Roche Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2021-2026)
- 12.2.4 F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
- 12.2.5 F. Hoffmann-La Roche Recent Developments
- 12.3 Agilent
- 12.3.1 Agilent Company Information
- 12.3.2 Agilent Business Overview
- 12.3.3 Agilent Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2021-2026)
- 12.3.4 Agilent Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
- 12.3.5 Agilent Recent Developments
- 12.4 Abbott
- 12.4.1 Abbott Company Information
- 12.4.2 Abbott Business Overview
- 12.4.3 Abbott Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2021-2026)
- 12.4.4 Abbott Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
- 12.4.5 Abbott Recent Developments
- 12.5 Thermo Fisher Scientific
- 12.5.1 Thermo Fisher Scientific Company Information
- 12.5.2 Thermo Fisher Scientific Business Overview
- 12.5.3 Thermo Fisher Scientific Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2021-2026)
- 12.5.4 Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
- 12.5.5 Thermo Fisher Scientific Recent Developments
- 12.6 Qiagen
- 12.6.1 Qiagen Company Information
- 12.6.2 Qiagen Business Overview
- 12.6.3 Qiagen Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2021-2026)
- 12.6.4 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
- 12.6.5 Qiagen Recent Developments
- 12.7 Guardant Health
- 12.7.1 Guardant Health Company Information
- 12.7.2 Guardant Health Business Overview
- 12.7.3 Guardant Health Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2021-2026)
- 12.7.4 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
- 12.7.5 Guardant Health Recent Developments
- 12.8 MGI Tech
- 12.8.1 MGI Tech Company Information
- 12.8.2 MGI Tech Business Overview
- 12.8.3 MGI Tech Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2021-2026)
- 12.8.4 MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
- 12.8.5 MGI Tech Recent Developments
- 12.9 Amoy Diagnostics
- 12.9.1 Amoy Diagnostics Company Information
- 12.9.2 Amoy Diagnostics Business Overview
- 12.9.3 Amoy Diagnostics Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2021-2026)
- 12.9.4 Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
- 12.9.5 Amoy Diagnostics Recent Developments
- 12.10 BGI Group
- 12.10.1 BGI Group Company Information
- 12.10.2 BGI Group Business Overview
- 12.10.3 BGI Group Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2021-2026)
- 12.10.4 BGI Group Pharmacogenomics Technology (Theranostics & CDx) Product Portfolio
- 12.10.5 BGI Group Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst